Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 10/20 | 0.62 |
| ▸ | ACLY | P53396 | 4/20 | 0.57 |
| ▸ | ACMSD | Q8TDX5 | 3/20 | 0.55 |
| ▸ | HNF4A | P41235 | 2/20 | 0.55 |
| ▸ | DHFR | P00374 | 1/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.51 |
| ▸ | CHUK | O15111 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | CDC7 | O00311 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1316465 | 0.99 | HDAC1 (0.63) | HDAC1ACLYACMSDHNF4ADHFR | |
| SCHEMBL1317748 | 0.91 | HDAC1 (0.60) | HDAC1ACLYACMSDHNF4AHDAC2 | |
| SCHEMBL1318525 | 0.91 | ACLY (0.67) | HDAC1ACLYACMSDHNF4ADHFR | |
| SCHEMBL1316020 | 0.88 | HDAC1 (0.62) | HDAC1ACLYACMSDHNF4ADHFR | |
| SCHEMBL1316942 | 0.88 | HDAC1 (0.59) | HDAC1ACLYACMSDHNF4ADHFR | |
| SCHEMBL1319925 | 0.87 | ACLY (0.56) | HDAC1ACLYACMSDHNF4ADHFR | |
| SCHEMBL1315416 | 0.87 | ACLY (0.59) | HDAC1ACLYACMSDHNF4ADHFR | |
| SCHEMBL1317382 | 0.87 | ACLY (0.50) | HDAC1ACLYMCL1 | |
| SCHEMBL1317590 | 0.85 | ACLY (0.51) | HDAC1ACLYMCL1 | |
| SCHEMBL1317109 | 0.85 | HDAC1 (0.58) | HDAC1ACLYACMSDHNF4ADHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102333757-B | N-acyl anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO LTD | 2014-11-26 | — | — | CN | disclosed |
| US-8492582-B2 | N-acyl anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-07-23 | — | — | US | disclosed |
| CN-102333757-A | N-acyl anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO LTD | 2012-01-25 | — | — | CN | disclosed |
| US-20110275797-A1 | N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-11-10 | — | — | US | disclosed |
| EP-2385036-A1 | N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | Toyama Chemical Co., Ltd. (JP) | 2011-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275797-A1 | N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | COL14A1, COL2A1, COL1A1 | HDAC1 73/4885ACLY 295/4885ACMSD 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.